• Study reveals new therapeutic option for

    From ScienceDaily@1:317/3 to All on Tue Apr 19 22:30:42 2022
    Study reveals new therapeutic option for head and neck carcinomas

    Date:
    April 19, 2022
    Source:
    Medical University of Vienna
    Summary:
    The various manifestations of head and neck carcinomas rank sixth
    in frequency worldwide and are fatal for about half a million
    people every year. In a quarter of cases, head and neck squamous
    cell carcinoma (HNSCC) is caused by human papillomavirus (HPV)
    and, currently, is not always treatable. A research team has now
    discovered a possible new therapeutic option.



    FULL STORY ==========================================================================
    The various manifestations of head and neck carcinomas rank sixth in
    frequency worldwide and are fatal for about half a million people every
    year. In a quarter of cases, head and neck squamous cell carcinoma
    (HNSCC) is caused by human papillomavirus (HPV) and, currently, is not
    always treatable. A research team led by Lorenz Kadletz-Wanke from MedUni Vienna's Department of Otorhinolaryngology and Head and Neck Surgery
    has now discovered a new therapeutic option in the context of a study.


    ==========================================================================
    In the course of their investigations, the researchers were able to
    identify a protein that can be used to predict above-average survival
    of patients with HPV-positive head and neck carcinoma and to achieve
    progress in treatment.

    Specifically, this involves the Creb-binding protein (CBP), which controls various cellular programs and plays a role in carcinogenesis, among other things. As the study shows, CBP is much more active in HPV-induced head
    and neck tumours.

    Prognostic marker The most common triggers of head and neck tumours
    continue to be alcohol consumption and smoking. That said, human
    papillomavirus infections have increasingly been identified as the cause
    of HNSCC in recent years. Patients with HPV-positive head and neck tumours
    have so far been treated with chemotherapy and radiotherapy. This standard method acts systemically, i.e. on the whole body, is often accompanied
    by serious side effects such as hair loss, nausea and anemia, and not
    all patients respond to it. In the search for targeted treatments, the interdisciplinary research group studied the tissue of patients with HPV-positive HNSCC tumours histologically and in preclinical models. In
    the process, they not only discovered the protein CBP as a prognostic
    marker for above-average patient survival but also found that HPV-
    positive HNSCC cell models in particular can be effectively treated with
    a CBP inhibitor.

    Targeted therapy CBP inhibitors are drugs currently in development and may
    be available within the next few years. "For patients with HPV-positive
    head and neck carcinoma, treatment with CBP inhibitors has the advantage
    that it can be targeted, rather than affecting the whole body. It is
    also better tolerated than conventional chemotherapy or radiotherapy and
    this would significantly improve the quality of life of those affected,"
    says study leader Lorenz Kadletz-Wanke, summarising the key finding
    of the research, which was conducted at MedUni Vienna's Department of Otorhinolaryngology and Head and Neck Surgery in collaboration with Lukas Kenner (MedUni Vienna's Department of Pathology, Department of Laboratory Animal Pathology at Vetmeduni Vienna) and Stefan Stoiber (MedUni Vienna's Department of Biomedical Imaging and Image-guided Therapy).


    ========================================================================== Story Source: Materials provided by Medical_University_of_Vienna. Note:
    Content may be edited for style and length.


    ========================================================================== Journal Reference:
    1. Faris F. Brkic, Stefan Stoiber, Tobias Maier, Elisabeth Gurnhofer,
    Lukas
    Kenner, Gregor Heiduschka, Lorenz Kadletz-Wanke. Targeting Wnt/Beta-
    Catenin Signaling in HPV-Positive Head and Neck Squamous Cell
    Carcinoma.

    Pharmaceuticals, 2022; 15 (3): 378 DOI: 10.3390/ph15030378 ==========================================================================

    Link to news story: https://www.sciencedaily.com/releases/2022/04/220419103227.htm

    --- up 7 weeks, 1 day, 10 hours, 51 minutes
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)